Geode Capital Management LLC Purchases 45,566 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Geode Capital Management LLC boosted its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 4.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,094,015 shares of the biotechnology company's stock after buying an additional 45,566 shares during the quarter. Geode Capital Management LLC owned approximately 2.45% of United Therapeutics worth $391,459,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the stock. Tri Locum Partners LP acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at $15,959,000. Bridgewater Associates LP boosted its position in United Therapeutics by 384.3% in the third quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company's stock valued at $22,130,000 after buying an additional 49,003 shares in the last quarter. Renaissance Technologies LLC grew its stake in United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company's stock worth $692,748,000 after buying an additional 22,978 shares during the last quarter. Vontobel Holding Ltd. grew its stake in United Therapeutics by 90.4% during the third quarter. Vontobel Holding Ltd. now owns 1,664 shares of the biotechnology company's stock worth $596,000 after buying an additional 790 shares during the last quarter. Finally, Glenmede Trust Co. NA increased its holdings in shares of United Therapeutics by 6.4% during the third quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company's stock worth $24,585,000 after buying an additional 4,145 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Performance

UTHR traded up $0.20 during trading on Friday, reaching $361.81. 293,245 shares of the company's stock were exchanged, compared to its average volume of 268,515. The company's fifty day moving average price is $369.94 and its 200-day moving average price is $342.19. The firm has a market capitalization of $16.15 billion, a PE ratio of 15.89, a P/E/G ratio of 1.05 and a beta of 0.54. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million during the quarter, compared to analysts' expectations of $722.62 million. During the same period in the previous year, the firm earned $5.38 earnings per share. The firm's quarterly revenue was up 22.9% compared to the same quarter last year. Research analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on UTHR shares. TD Cowen increased their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Argus increased their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price target on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a report on Thursday, October 31st. StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Thursday, October 17th. Finally, HC Wainwright raised their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $370.86.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $374.37, for a total value of $2,882,649.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares in the company, valued at $13,743,122.70. This represents a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher Causey sold 510 shares of the firm's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the sale, the director now directly owns 3,675 shares in the company, valued at approximately $1,384,115.25. This represents a 12.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 119,340 shares of company stock valued at $44,765,530 in the last ninety days. 11.90% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.